Anti-Human CD319 (SLAMF7) (Elotuzumab) (C1060-GRP)

CD319 is a cell surface glycoprotein that is a member of the immunoglobulin gene superfamily and is universally highly expressed on multiple myeloma (MM) cells, where it functions in human MM cell adhesion1. Since it is not detectable in healthy donor samples, CD319 has been targeted for the development of MM immunotherapy1, 2. Elotuzumab is a humanized monoclonal antibody against CD319 that was developed as a MM immunotherapeutic1, 2. Elotuzumab was generated by immunizing female BALB/c mice with purified CD319 protein2. Spleen cells were fused to the P3X63Ag8 fusion partner, and the resulting hybridomas were screened. Murine MuLuc63 was identified as CD319 specific and Humanized. Elotuzumab activity is mediated through antibody-dependent cellular cytotoxicity and direct NK cell activation1, 2, 3, 4. In vitro, elotuzumab inhibits binding of MM cells to bone marrow stromal cells and in vivo it inhibits tumor progression in murine xenografts and clinical trials1, 2, 4. Additionally, elotuzumab inhibits proliferation and survival of MM cells1. Elotuzumab also induces IFN-γ production3. In flow cytometry analysis of MM samples, elotuzumab binds strongly to the majority of plasma cells2. In contrast, in healthy donors, elotuzumab primarily binds D3+CD16+CD56+ NK-like T cells, CD3-CD16+CD56+ NK cells, and approximately half of CD3+CD8+ T cells. Additionally, low levels of binding are detected on CD3+CD8- T cells and none on monocytes (CD14+HLA-DR+), B cells (CD20+HLA-DR+), or granulocytes (CD13+CD45+). Elotuzumab has been approved for the treatment of some patients with multiple myeloma 4.